Hydrogen Sulfide Ameliorates Homocysteine-Induced Alzheimer's Disease-Like Pathology, Blood-Brain Barrier Disruption, and Synaptic Disorder

被引:330
|
作者
Kamat, Pradip K. [1 ]
Kyles, Philip [1 ]
Kalani, Anuradha [1 ]
Tyagi, Neetu [1 ,2 ]
机构
[1] Univ Louisville, Dept Physiol & Biophys, Sch Med, Louisville, KY 40202 USA
[2] Univ Louisville, Hlth Sci Ctr, Dept Physiol & Biophys, A-1201, Louisville, KY 40202 USA
基金
美国国家卫生研究院;
关键词
Homocysteine; Blood-brain barrier dysfunction; Cerebrovascular pathology; Alzheimer's disease; Dementia; INDUCED MEMORY IMPAIRMENT; PLASMA HOMOCYSTEINE; MATRIX METALLOPROTEINASES; COGNITIVE PERFORMANCE; RECEPTOR TRAFFICKING; RISK-FACTOR; RAT-BRAIN; MATRIX-METALLOPROTEINASE-9; EXPRESSION; DEMENTIA;
D O I
10.1007/s12035-015-9212-4
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Elevated plasma total homocysteine (Hcy) level is associated with an increased risk of Alzheimer's disease (AD). During transsulfuration pathways, Hcy is metabolized into hydrogen sulfide (H2S), which is a synaptic modulator, as well as a neuro-protective agent. However, the role of hydrogen sulfide, as well as N-methyl-d-aspartate receptor (NMDAR) activation, in hyperhomocysteinemia (HHcy) induced blood-brain barrier (BBB) disruption and synaptic dysfunction, leading to AD pathology is not clear. Therefore, we hypothesized that the inhibition of neuronal NMDA-R by H2S and MK801 mitigate the Hcy-induced BBB disruption and synapse dysfunction, in part by decreasing neuronal matrix degradation. Hcy intracerebral (IC) treatment significantly impaired cerebral blood flow (CBF), and cerebral circulation and memory function. Hcy treatment also decreases the expression of cystathionine-beta-synthase (CBS) and cystathionine-gamma-lyase (CSE) in the brain along with increased expression of NMDA-R (NR1) and synaptosomal Ca2+ indicating excitotoxicity. Additionally, we found that Hcy treatment increased protein and mRNA expression of intracellular adhesion molecule 1 (ICAM-1), matrix metalloproteinase (MMP)-2, and MMP-9 and also increased MMP-2 and MMP-9 activity in the brain. The increased expression of ICAM-1, glial fibrillary acidic protein (GFAP), and the decreased expression of vascular endothelial (VE)-cadherin and claudin-5 indicates BBB disruption and vascular inflammation. Moreover, we also found decreased expression of microtubule-associated protein 2 (MAP-2), postsynaptic density protein 95 (PSD-95), synapse-associated protein 97 (SAP-97), synaptosomal-associated protein 25 (SNAP-25), synaptophysin, and brain-derived neurotrophic factor (BDNF) showing synapse dysfunction in the hippocampus. Furthermore, NaHS and MK801 treatment ameliorates BBB disruption, CBF, and synapse functions in the mice brain. These results demonstrate a neuro-protective effect of H2S over Hcy-induced cerebrovascular pathology through the NMDA receptor. Our present study clearly signifies the therapeutic ramifications of H2S for cerebrovascular diseases such as Alzheimer's disease.
引用
收藏
页码:2451 / 2467
页数:17
相关论文
共 50 条
  • [41] Blood-brain barrier dysfunction as a cause and consequence of Alzheimer's disease
    Erickson, Michelle A.
    Banks, William A.
    JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2013, 33 (10) : 1500 - 1513
  • [42] Breakdown of the Cerebrovasculature and Blood-Brain Barrier: A Mechanistic Link Between Diabetes Mellitus and Alzheimer's Disease
    Goldwaser, Eric L.
    Acharya, Nimish K.
    Sarkar, Abhirup
    Godsey, George
    Nagele, Robert G.
    JOURNAL OF ALZHEIMERS DISEASE, 2016, 54 (02) : 445 - 456
  • [43] Amyloid-β Peptides, Alzheimer's Disease and the Blood-brain Barrier
    Gosselet, Fabien
    Saint-Pol, Julien
    Candela, Pietra
    Fenart, Laurence
    CURRENT ALZHEIMER RESEARCH, 2013, 10 (10) : 1015 - 1033
  • [44] The Case for Blood-Brain Barrier Dysfunction in the Pathogenesis of Alzheimer's Disease
    Jeynes, Brian
    Provias, John
    JOURNAL OF NEUROSCIENCE RESEARCH, 2011, 89 (01) : 22 - 28
  • [45] High-fat diet protects the blood-brain barrier in an Alzheimer's disease mouse model
    Goldman, Shirin Elhaik
    Goez, David
    Last, David
    Naor, Sharone
    Zaltsman, Sigal Liraz
    Sharvit-Ginon, Inbal
    Atrakchi-Baranes, Dana
    Shemesh, Chen
    Twitto-Greenberg, Rachel
    Tsach, Shoval
    Lotan, Roni
    Leikin-Frenkel, Alicia
    Shish, Aviv
    Mardor, Yael
    Beeri, Michal Schnaider
    Cooper, Itzik
    AGING CELL, 2018, 17 (05)
  • [46] Vascular Risk Factors and Alzheimer's Disease: Blood-Brain Barrier Disruption, Metabolic Syndromes, and Molecular Links
    He, Jin-Ting
    Zhao, Xin
    Xu, Lei
    Mao, Cui-Ying
    JOURNAL OF ALZHEIMERS DISEASE, 2020, 73 (01) : 39 - 58
  • [47] Blood-Brain Barrier Penetrating Biologic TNF-α Inhibitor for Alzheimer's Disease
    Chang, Rudy
    Knox, Jillian
    Chang, Jae
    Derbedrossian, Aram
    Vasilevko, Vitaly
    Cribbs, David
    Boado, Ruben J.
    Pardridge, William M.
    Sumbria, Rachita K.
    MOLECULAR PHARMACEUTICS, 2017, 14 (07) : 2340 - 2349
  • [48] Blood-brain barrier permeability is associated with different neuroinflammatory profiles in Alzheimer's disease
    Bruno, Matilde
    Bonomi, Chiara Giuseppina
    Ricci, Francesco
    Di Donna, Martina Gaia
    Mercuri, Nicola Biagio
    Koch, Giacomo
    Martorana, Alessandro
    Motta, Caterina
    EUROPEAN JOURNAL OF NEUROLOGY, 2024, 31 (01)
  • [49] Folic acid and S-adenosylmethionine reverse Homocysteine-induced Alzheimer's disease-like pathological changes in rat hippocampus by modulating PS1 and PP2A methylation levels
    Sun, Shoudan
    Lu, Wei
    Zhang, Chunhong
    Wang, Guanyu
    Hou, Yue
    Zhou, Jian
    Wang, Yonghui
    BRAIN RESEARCH, 2024, 1841
  • [50] Alzheimer's disease drug development and the problem of the blood-brain barrier
    Pardridge, William A.
    ALZHEIMERS & DEMENTIA, 2009, 5 (05) : 427 - 432